AVXL
ANAVEX LIFE SCIENCES CORP.Figures below are compared against other companies classified under Biological Products, (No Diagnostic Substances).
Grades vs. industry
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 74.3% | — |
Operating margin Operating income as a share of revenue. | Not reported | -19.1% | — |
Net margin Net income as a share of revenue. | Not reported | -17.7% | — |
Free cash flow margin Free cash flow as a share of revenue. | Not reported | -22.3% | — |
Return on equity Net income divided by shareholder equity. | -48.9% | -16.5% | — |
Return on assets Net income divided by total assets. | -44.7% | -8.0% | — |
Return on invested capital After-tax operating profit over debt plus equity less cash. | Not reported | -13.0% | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 4 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 24, 2026 | Boenisch Sandra PFO & Treasurer | Grant or award(derivative) | 20,000 | $0.00 | $0.00 |
| Sep 24, 2026 | Boenisch Sandra PFO & Treasurer | Grant or award(derivative) | 25,000 | $0.00 | $0.00 |
| Sep 24, 2026 | Boenisch Sandra PFO & Treasurer | Grant or award(derivative) | 25,000 | $0.00 | $0.00 |
| Sep 24, 2026 | Boenisch Sandra PFO & Treasurer | Grant or award(derivative) | 25,000 | $0.00 | $0.00 |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$51.41M | -$52.88M | -$55.76M | -$50.99M | -$42.00M | -$31.09M | — | — | — | — |
| Net income | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -$37.91M | -$26.28M | -$26.29M | -$17.25M | -$13.46M | -$14.74M |
| EPS (diluted) | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | -$0.45 | -$0.54 | -$0.39 | -$0.33 | -$0.42 |
| Operating cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -$30.38M | -$21.29M | -$18.53M | -$12.58M | -$9.02M | -$9.24M |
| Total assets | $103.81M | $135.57M | $154.39M | $152.71M | $161.62M | $34.54M | $25.33M | $26.21M | $27.84M | $9.50M |
| Shareholder equity | $94.87M | $120.26M | $141.85M | $142.49M | $150.82M | $27.24M | $20.29M | $22.32M | $25.88M | $6.31M |
| Cash | $102.58M | $132.19M | $151.02M | $149.16M | $152.11M | $29.25M | $22.19M | $22.93M | $27.44M | $9.19M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Source
Figures come from ANAVEX LIFE SCIENCES CORP.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K/A filed Aug 28, 2026. View filings on EDGAR.